Mercy General Hospital

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Aortic stenosis4 trials
• Atrial fibrillation3 trials
• Head and neck cancer1 trial
• Lung cancer1 trial
• Ovarian cancer1 trial
• Stroke1 trial

Phase

• Phase 33 trials

Status

• Active, not recruiting5 trials
• Completed5 trials

Lead sponsor

• Edwards Lifesciences2 trials
• Abbott Medical Devices1 trial
• Boston Scientific Corporation1 trial
• ETOP IBCSG Partners Foundation1 trial
• Medtronic Cardiac Ablation Solutions1 trial
• and 4 more

Running trials

• Active, not recruiting

  Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)

  NCT07308847· Medtronic Cardiac Ablation Solutions· Source

• Active, not recruiting

  Treatment of PAF With the Synaptic System

  NCT05905835· Synaptic Medical Corporation· Source

• Active, not recruiting

  CHAMPION-AF Clinical Trial

  NCT04394546· Boston Scientific Corporation· Source

• Active, not recruiting

  Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

  NCT02701283· Medtronic Cardiovascular· Source

• Active, not recruiting

  Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial

  NCT02000115· Abbott Medical Devices· Source

Closed trials

• Completed

  PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - S3 Intermediate

  NCT03222128· Edwards Lifesciences· Source

• Completed

  Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

  NCT01302834· Phase 3· Radiation Therapy Oncology Group· Source

• Completed

  PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk

  NCT01314313· Edwards Lifesciences· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

  NCT00066690· Phase 3· ETOP IBCSG Partners Foundation· Source